Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CSF1/CSF1R signaling mediates malignant pleural effusion formation
Chrysavgi N. Kosti, Photene C. Vaitsi, Apostolos G. Pappas, Marianthi P. Iliopoulou, Katherina K. Psarra, Sophia F. Magkouta, Ioannis T. Kalomenidis
Chrysavgi N. Kosti, Photene C. Vaitsi, Apostolos G. Pappas, Marianthi P. Iliopoulou, Katherina K. Psarra, Sophia F. Magkouta, Ioannis T. Kalomenidis
View: Text | PDF
Research Article Angiogenesis Oncology

CSF1/CSF1R signaling mediates malignant pleural effusion formation

  • Text
  • PDF
Abstract

Malignant pleural effusion (MPE) is an incurable common manifestation of many malignancies. Its formation is orchestrated by complex interactions among tumor cells, inflammatory cells, and the vasculature. Tumor-associated macrophages present the dominant inflammatory population of MPE, and M2 macrophage numbers account for dismal prognosis. M2 polarization is known to be triggered by CSF1/CSF1 receptor (CSF1R) signaling. We hypothesized that CSF1R+ M2 macrophages favor MPE formation and could be therapeutically targeted to limit MPE. We generated mice with CSF1R-deficient macrophages and induced lung and colon adenocarcinoma–associated MPE. We also examined the therapeutic potential of a clinically relevant CSF1R inhibitor (BLZ945) in lung and colon adenocarcinoma–induced experimental MPE. We showed that CSF1R+ macrophages promoted pleural fluid accumulation by enhancing vascular permeability, destabilizing tumor vessels, and favoring immune suppression. We also showed that CSF1R inhibition limited MPE in vivo by reducing vascular permeability and neoangiogenesis and impeding tumor progression. This was because apart from macrophages, CSF1R signals in cancer-associated fibroblasts leading to macrophage inflammatory protein 2 secretion triggered the manifestation of suppressive and angiogenic properties in macrophages upon CXCR2 paracrine activation. Pharmacological targeting of the CSF1/CSF1R axis can therefore be a vital strategy for limiting MPE.

Authors

Chrysavgi N. Kosti, Photene C. Vaitsi, Apostolos G. Pappas, Marianthi P. Iliopoulou, Katherina K. Psarra, Sophia F. Magkouta, Ioannis T. Kalomenidis

×

Figure 1

CSF1R+ macrophages promote MPE accumulation by enhancing pleural vascular permeability and destabilizing tumor vessels.

Options: View larger image (or click on image) Download as PowerPoint
CSF1R+ macrophages promote MPE accumulation by enhancing pleural vascula...
C57BL/6 mice whose macrophages were devoid of CSF1R (LysM-Crehemi CSF1Rfl/fl) were created as described in Methods. LysM-Cre–/– CSF1Rfl/fl mice, whose macrophages are able to express CSF1R, were used as positive controls. MPE was induced upon intrapleural delivery of 1.5 × 105 Lewis lung cells (LLCs) or MC38 murine adenocarcinoma cells. Animals were euthanized 13 days later. (A) Pleural fluid was retrieved and quantified. (B) Total pleural cell numbers were determined under a hematocytometer. Data presented as mean ± SEM. LLC: LysM-Crehemi CSF1Rfl/fl n = 11, LysM-Cre–/– CSF1Rfl/fl n = 5. MC38: LysM-Crehemi CSF1Rfl/fl n = 10, LysM-Cre–/– CSF1Rfl/fl n = 7. *P < 0.05 compared with LysM-Crehemi CSF1Rfl/fl by 2-tailed Student’s t test. (C) Pleural vascular permeability was evaluated after intrapleural injection of Evans blue. Data presented as mean ± SEM. LLC: LysM-Crehemi CSF1Rfl/fl n = 4, LysM-Cre–/– CSF1Rfl/fl n = 5. MC38: LysM-Crehemi CSF1Rfl/fl n = 4, LysM-Cre–/– CSF1Rfl/fl n = 5. *P < 0.05 compared with LysM-Crehemi CSF1Rfl/fl by 2-tailed Student’s t test. (D and F) Tumor vessel networks were visualized upon CD31 immunofluorescence staining. (E and F) Vascular normalization was assessed by the ratio of VE-cadherin+CD31+ tumor areas quantified using the ImageJ software (NIH). (F) Representative images of VE-cadherin expression (green) by tumor vessels (red). Scale bar: 20 μm. Data presented as mean ± SEM. LLC: LysM-Crehemi CSF1Rfl/fl n = 6, LysM-Cre–/– CSF1Rfl/fl n = 4. MC38: LysM-Crehemi CSF1Rfl/fl n = 5, LysM-Cre–/– CSF1Rfl/fl n = 5. *P < 0.05 compared with LysM-Crehemi CSF1Rfl/fl by 2-tailed Student’s t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts